Gefarnate
 | |
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.000.111 |
| Chemical and physical data | |
| Formula | C27H44O2 |
| Molar mass | 400.637 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Gefarnate is a drug used for the treatment of gastric ulcers.[1]
It also has been proposed for use in the treatment of dry eye syndrome.[2][3]
References
- ^ Ohta Y, Kobayashi T, Imai Y, Inui K, Yoshino J, Nakazawa S (August 2005). "Effect of gefarnate on acute gastric mucosal lesion progression in rats treated with compound 48/80, a mast cell degranulator, in comparison with that of teprenone". Biol. Pharm. Bull. 28 (8): 1424–30. doi:10.1248/bpb.28.1424. PMID 16079487.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Peral A, Domínguez-Godínez CO, Carracedo G, Pintor J (April 2008). "Therapeutic targets in dry eye syndrome". Drug News Perspect. 21 (3): 166–76. PMID 18560615.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Gipson IK, Hori Y, Argüeso P (April 2004). "Character of ocular surface mucins and their alteration in dry eye disease". Ocul Surf. 2 (2): 131–48. doi:10.1016/s1542-0124(12)70149-0. PMID 17216084.
{{cite journal}}: CS1 maint: multiple names: authors list (link)
 | This article about an alkene is a stub. You can help Wikipedia by expanding it. |
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |